Sasaki Hikaru, Yoshida Kazunari
Department of Neurosurgery, Keio University School of Medicine.
Neurol Med Chir (Tokyo). 2017 Dec 15;57(12):658-666. doi: 10.2176/nmc.ra.2017-0071. Epub 2017 Aug 25.
With advanced understanding of molecular background and correlation with therapeutic outcomes, the revised 4th edition of World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporated molecular information into the definition of diffuse gliomas. Indeed, oligodendroglioma and astrocytoma are now defined by molecular signature, with diagnosis of glioblastoma being made by histology. In parallel, numerous clinical trials are underway all over the world, and important findings are being produced every year that have an impact on patient outcomes. Moreover, novel therapies/technologies are also being actively developed; however, there are still many CNS tumors for which no effective therapy has been established except radiotherapy. In this article, the authors review the recent results of major clinical trials and present their treatment recommendations for patients with adult, supratentorial diffuse gliomas of grades II and III stratified according to the new WHO classification.
随着对分子背景的深入理解以及与治疗结果的相关性研究，世界卫生组织（WHO）中枢神经系统（CNS）肿瘤分类的修订第4版将分子信息纳入了弥漫性胶质瘤的定义中。事实上，少突胶质细胞瘤和星形细胞瘤现在由分子特征定义，而胶质母细胞瘤则通过组织学诊断。与此同时，世界各地正在进行大量临床试验，每年都有重要发现影响患者的治疗结果。此外，新的治疗方法/技术也在积极研发；然而，除了放射治疗外，仍有许多中枢神经系统肿瘤尚未建立有效的治疗方法。在本文中，作者回顾了主要临床试验的近期结果，并针对根据WHO新分类分层的II级和III级成人幕上弥漫性胶质瘤患者提出了治疗建议。
